MITSUBISHI-HEAVY-IND
18.4.2019 09:23:11 CEST | Business Wire | Press release
Premiering for the first time in the world, Mitsubishi Heavy Industries Thermal Systems, Ltd., a Group company of Mitsubishi Heavy Industries, Ltd. (MHI) (TOKYO: 7011), is adopting R454C, a refrigerant with an extremely low global warming potential (GWP), in a 1-horsepower (HP) class residential air-conditioner. The conventional shortcomings of the R454C,for example; inferior heat exchanger performance attributable to it being a mixed refrigerant have been overcome through the use of proprietary technology that optimize the heat exchanger’s flow volume and other measures. The company has already developed a demonstration unit of the residential air-conditioner featuring R454C and preparations are underway towards mass production with an eye on an initial launch into the European market, where environmental regulations are particularly stringent.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190418005241/en/
The R454C refrigerant has an ozone depletion potential (ODP) of 0 (zero) and a GWP of 146 (CO2 =1). The latter value is approximately 1/14th and 1/5th the respective GWP levels of refrigerants currently and most widely used in air-conditioners of small/medium scale: R410A (2090) and R32 (675). The overall global warming impact (GWP x refrigerant volume) from the demonstration unit’s refrigerant represents a 91.3% reduction from the level of MHI Thermal Systems’ previous model for the European market*1 .
Worldwide initiatives aimed at stopping global warming were strengthened in October 2016 with the adoption of the “Kigali Amendment” to the Montreal Protocol on Substances that Deplete the Ozone Layer. Named after the capital city of Rwanda where the delegates met, the Kigali Amendment mandates progressive reduction in hydrofluorocarbons (HFC), substances that do not deplete the ozone but do adversely impact global warming*2 . In addition, since 2015 the member nations of the European Union (EU), where environmental awareness is deeply entrenched, have gradually expanded regulations affecting the sale and usage of substances, including HFCs, that have GWP values of 150 and higher, contributing to global warming. MHI Thermal Systems’ development of the world’s first small-capacity residential air-conditioner adopting the R454C refrigerant is thus a leading and positive response to these international movements.
Going forward, MHI Thermal Systems will continue to dedicate its resources to developing and marketing high-performance products using low-GWP refrigerants, thereby contributing to protection of the global environment in markets everywhere.
|
Notes |
||||
|
*1: |
The top-of-the-line SRK25ZSX-S with a piping length of 5m, which adopts the R410A refrigerant |
|||
|
*2: |
These substances are subject to the terms of both the Montreal Protocol (1987) and the preceding Vienna Convention for the Protection of the Ozone Layer (1985). |
|||
About Mitsubishi Heavy Industries Group
Mitsubishi Heavy Industries, Ltd. (MHI), headquartered in Tokyo, is one
of the world’s leading industrial firms with 80,000 group employees and
annual consolidated revenues of around 38 billion U.S. dollars. For more
than 130 years, the company has channeled big thinking into innovative
and integrated solutions that move the world forward. MHI owns a unique
business portfolio covering land, sea, sky and even space. MHI delivers
innovative and integrated solutions across a wide range of industries
from commercial aviation and transportation to power plants and gas
turbines, and from machinery and infrastructure to integrated defense
and space systems.
For more information, please visit MHI’s
website: www.mhi.com/index.html
For
Technology, Trends and Tangents, visit MHI’s new online media SPECTRA
:
spectra.mhi.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190418005241/en/
Contact:
PRESS CONTACT: Corporate Communication Department Mitsubishi Heavy Industries, Ltd. James Bennett, +81-(0)3-6275-6200 Email: mediacontact_global@mhi.co.jp
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom